Company intelligence / Profile preview

EUSA Pharma

Hemel Hempstead/Oxford, United Kingdomleadiq.com ↗

Ownership: Private
Employees: ~200
Development stage: Other

Overview

EUSA Pharma has a portfolio of four rare and niche oncology products, including commercialized monoclonal antibodies for high-risk neuroblastoma and iMCD. The company has demonstrated strong growth in rare disease markets with global reach, particularly in Europe and the US.

Therapeutic areas: HematologyOncology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Drug pipeline

15 assets

capromab pendetide

Approved

14 more assets in the full pipeline.

Request access →

Partnerships

GlaxoSmithKline

Beyond the preview

Go deeper on EUSA Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EUSA Pharma.

Explore the full profile